PT - JOURNAL ARTICLE AU - Jennifer C.E.Lane AU - James Weaver AU - Kristin Kostka AU - Talita Duarte-Salles AU - Maria Tereza F. Abrahao AU - Heba Alghoul AU - Osaid Alser AU - Thamir M Alshammari AU - Patricia Biedermann AU - Edward Burn AU - Paula Casajust AU - Mitch Conover AU - Aedin C. Culhane AU - Alexander Davydov AU - Scott L. DuVall AU - Dmitry Dymshyts AU - Sergio Fernandez-Bertolin AU - Kristina Fišter AU - Jill Hardin AU - Laura Hester AU - George Hripcsak AU - Seamus Kent AU - Sajan Khosla AU - Spyros Kolovos AU - Christophe G. Lambert AU - Johan van der Lei AU - Ajit A. Londhe AU - Kristine E. Lynch AU - Rupa Makadia AU - Andrea V. Margulis AU - Michael E. Matheny AU - Paras Mehta AU - Daniel R. Morales AU - Henry Morgan-Stewart AU - Mees Mosseveld AU - Danielle Newby AU - Fredrik Nyberg AU - Anna Ostropolets AU - Rae Woong Park AU - Albert Prats-Uribe AU - Gowtham A. Rao AU - Christian Reich AU - Jenna Reps AU - Peter Rijnbeek AU - Selva Muthu Kumaran Sathappan AU - Martijn Schuemie AU - Sarah Seager AU - Anthony Sena AU - Azza Shoaibi AU - Matthew Spotnitz AU - Marc A. Suchard AU - Joel Swerdel AU - Carmen O. Torre AU - David Vizcaya AU - Haini Wen AU - Marcel de Wilde AU - Seng Chan You AU - Lin Zhang AU - Oleg Zhuk AU - Patrick Ryan AU - Daniel Prieto-Alhambra AU - on behalf of OHDSI-COVID-19 consortium. TI - Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study AID - 10.1101/2020.04.08.20054551 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.08.20054551 4099 - http://medrxiv.org/content/early/2020/04/10/2020.04.08.20054551.short 4100 - http://medrxiv.org/content/early/2020/04/10/2020.04.08.20054551.full AB - Background Hydroxychloroquine has recently received Emergency Use Authorization by the FDA and is currently prescribed in combination with azithromycin for COVID-19 pneumonia. We studied the safety of hydroxychloroquine, alone and in combination with azithromycin.Methods New user cohort studies were conducted including 16 severe adverse events (SAEs). Rheumatoid arthritis patients aged 18+ and initiating hydroxychloroquine were compared to those initiating sulfasalazine and followed up over 30 days. Self-controlled case series (SCCS) were conducted to further establish safety in wider populations. Separately, SAEs associated with hydroxychloroquine- azithromycin (compared to hydroxychloroquine-amoxicillin) were studied. Data comprised 14 sources of claims data or electronic medical records from Germany, Japan, Netherlands, Spain, UK, and USA. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate calibrated hazard ratios (CalHRs) according to drug use. Estimates were pooled where I2<40%.Results Overall, 956,374 and 310,350 users of hydroxychloroquine and sulfasalazine, and 323,122 and 351,956 users of hydroxychloroquine-azithromycin and hydroxychloroquine-amoxicillin were included. No excess risk of SAEs was identified when 30-day hydroxychloroquine and sulfasalazine use were compared. SCCS confirmed these findings. However, when azithromycin was added to hydroxychloroquine, we observed an increased risk of 30-day cardiovascular mortality (CalHR2.19 [1.22- 3.94]), chest pain/angina (CalHR 1.15 [95% CI 1.05-1.26]), and heart failure (CalHR 1.22 [95% CI 1.02- 1.45])Conclusions Short-term hydroxychloroquine treatment is safe, but addition of azithromycin may induce heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length. We call for caution if such combination is to be used in the management of Covid-19.Trial registration number Registered with EU PAS; Reference number EUPAS34497 (http://www.encepp.eu/encepp/viewResource.htm?id=34498). The full study protocol and analysis source code can be found at https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine.Funding sources This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and Senior Research Fellowship (DPA), US National Institutes of Health, Janssen Research & Development, IQVIA, and by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number: HI16C0992]. Personal funding included Versus Arthritis [21605] (JL), MRC-DTP [MR/K501256/1] (JL), MRC and FAME (APU). The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. No funders had a direct role in this study. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, NHS or the Department of Health, England.Competing Interest Statementall authors have completed an ICJME formClinical TrialRegistered with EU PAS; Reference number EUPAS34497 (http://www.encepp.eu/encepp/viewResource.htm?id=34498). The full study protocol and analysis source code can be found at https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine.Clinical Protocols http://www.encepp.eu/encepp/viewResource.htm?id=34498 https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine.Funding StatementThis research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and Senior Research Fellowship (DPA), US National Institutes of Health, Janssen Research & Development, IQVIA, and by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number: HI16C0992]. Personal funding included Versus Arthritis [21605] (JL), MRC-DTP [MR/K501256/1] (JL), MRC and FAME (APU). The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. No funders had a direct role in this study. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, NHS or the Department of Health, England.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study was conducted as a distributed database network analysis. To protect patient privacy, all patient-level data were maintained securely behind institutional firewalls. Analysis code was downloaded and executed by each participating data partner, which generated only aggregate summary statistics (cohort counts, model coefficients) which were then centralized and synthesized in preparation of this manuscript. All aggregate summary statistics produced have been made publicly available at: https://data.ohdsi.org/Covid19EstimationHydroxychloroquine/. https://data.ohdsi.org/Covid19EstimationHydroxychloroquine/ https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine https://github.com/ohdsi-studies/Covid19DrugRepurposing